FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Data Backs Pulmonary Hypertension Drug: Merck

Merck reports positive top-line results from a pivotal Phase 3 trial (STELLAR) evaluating the safety and efficacy of sotatercept, an investigational d...

latest-news-card-1
Federal Register

Priority Review Voucher Fee Rate Set

Federal Register notice: FDA announces the fee rate for using a priority review voucher for fiscal year 2023.

latest-news-card-1
Federal Register

Guides on Device Surveillance/Post-approval Studies

Federal Register notice: FDA makes available final guidances on postmarket surveillance and post-approval study orders.

latest-news-card-1
Human Drugs

scPharmaceuticals Gets Heart Failure Drug Approved

FDA approves scPharmaceuticals Furoscix (furosemide injection) for treating congestion due to fluid overload in adults with New York Heart Association...

latest-news-card-1
Medical Devices

FDA Clears Zeiss Medicals Bipolar Forceps

Zeiss Medical Technology gains 510(k) clearance for MTLawton, disposable bipolar forceps made from a copper-base alloy.

latest-news-card-1
Medical Devices

FDA Clears Copan Diagnostics Colibr

FDA clears a Copan Diagnostics 510(k) for its Colibr, a semi-automated pre-analytical processor that is part of the companys WASPLab laboratory automa...

latest-news-card-1
Human Drugs

Miscarriage Management Needed on Mifeprex Label: Petititon

The American College of Obstetricians and Gynecologists and 48 other reproductive health organizations petition FDA to ask Danco Laboratories to submi...

latest-news-card-1
Biologics

Glaxos Boostrix OKd for Unborn in Third Trimester

FDA approves GlaxoSimthKline Biologicals Boostrix vaccine to immunize, during the third trimester, unborn children against pertussis.

latest-news-card-1
Federal Register

FDA Proposal to Destroy Devices Refused U.S. Entry

Federal Register proposed rule: FDA proposes a regulation to implement its new authority to destroy a device valued at $2,500 or less that has been re...

latest-news-card-1
Federal Register

Biosimilar User Fee Rates Set for FY 2023

Federal Register notice: FDA announces the rates for biosimilar user fees for fiscal year 2023.